CytoMed Therapeutics Overview
Latest PEG ratio for CytoMed Therapeutics: -12.01 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-12.01
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for GDTC is -12.01. That is below the sector sector average of -2.26. Investors often review this figure alongside CytoMed Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, GDTC currently prints -12.01 for PEG ratio, while the sector average sits near -2.26. That is roughly 431.9% below the sector mean. Large gaps often invite a closer look at CytoMed Therapeutics's growth, margins, and balance sheet.
A PEG ratio of -12.01 for CytoMed Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (-2.26) and with GDTC's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting GDTC's PEG ratio (-12.01), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
